CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) shares fell 8.7% on Monday . The stock traded as low as $33.05 and last traded at $33.76. 679,792 shares traded hands during trading, a decline of 56% from the average session volume of 1,549,634 shares. The stock had previously closed at $36.99.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on CRSP. Evercore ISI raised CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and boosted their target price for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Truist Financial upped their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. JMP Securities reissued a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Cantor Fitzgerald restated a "neutral" rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, March 21st. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, CRISPR Therapeutics has an average rating of "Hold" and a consensus target price of $73.11.
Get Our Latest Research Report on CRISPR Therapeutics
CRISPR Therapeutics Stock Performance
The firm has a market capitalization of $2.67 billion, a price-to-earnings ratio of -7.13 and a beta of 1.85. The business's 50 day moving average is $42.15 and its 200-day moving average is $44.64.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.
Insider Transactions at CRISPR Therapeutics
In other news, COO Julianne Bruno sold 1,198 shares of the business's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the company's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at $9,473,037.60. This represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock worth $1,608,243 over the last three months. 4.10% of the stock is currently owned by insiders.
Hedge Funds Weigh In On CRISPR Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Wood Tarver Financial Group LLC bought a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $30,000. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics during the third quarter worth $40,000. Ameriflex Group Inc. bought a new stake in CRISPR Therapeutics in the 4th quarter valued at $36,000. Highline Wealth Partners LLC acquired a new position in shares of CRISPR Therapeutics in the 4th quarter valued at $39,000. Finally, Western Pacific Wealth Management LP lifted its holdings in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after acquiring an additional 500 shares during the period. 69.20% of the stock is currently owned by institutional investors.
CRISPR Therapeutics Company Profile
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Further Reading
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
